10x Genomics Q2 2024 GAAP EPS $(0.32) Beats $(0.48) Estimate, Sales $153.104M Beat $150.089M Estimate
Portfolio Pulse from Benzinga Newsdesk
10x Genomics (NASDAQ:TXG) reported Q2 2024 GAAP EPS of $(0.32), beating the $(0.48) estimate, and sales of $153.104M, surpassing the $150.089M estimate. This represents a significant improvement in both earnings and sales compared to the same period last year.
August 08, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
10x Genomics (NASDAQ:TXG) reported better-than-expected Q2 2024 results with GAAP EPS of $(0.32) beating the $(0.48) estimate and sales of $153.104M surpassing the $150.089M estimate. This indicates a significant improvement in both earnings and sales compared to the same period last year.
The better-than-expected earnings and sales figures indicate strong operational performance and could lead to positive investor sentiment, likely driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100